Is it safe to use antidepressants after a stroke?

Bibliography

• ANDERSEN G, VESTERGAARD K, INGEMANN-NIELSEN M, LAURITZEN L: Risk factors for post-stroke depression. Acta Psychiatr. Land. (1995) 92(3):193–198.
   PubMed Web of Science ®Google Scholar
• ANDERSEN G, VESTERGAARD K, LAURITZEN L: Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke (1994) 25(6):1099–1104.
   PubMed Web of Science ®Google Scholar
• WIART L, PETIT H, JOSEPH PA, MAZAUX JM, BARAT M: Fluoxetine in Early Poststroke Depression. A Double-Blind Placebo-Controlled Study. Stroke (2000) 31:1829.
   Google Scholar
• LYKETSOS CG, TREISMAN GJ, LIPSEY JR, MORRIS PL, ROBINSON RG: Does stroke cause depression? I Neuropsychiatry Neurosci. (1998) 10(1):103–107.
   Google Scholar
• ROBINSON RG: Neuropsychiatric consequences of stroke. Ann. Rev Med. (1997) 48:217–229.
   PubMed Web of Science ®Google Scholar
• ROBINSON RG, MORRIS PLP, FEDOROFF P: Depression and cerebrovascular disease. .1 Cliii. Psychiatry (1990) 51:26–31.
   PubMed Web of Science ®Google Scholar
• JOLOBE OM: Depression and its relation to lesion location after stroke. J. Neurol Neurosurg. Psychiatry (1998) 653):4l0.
   Google Scholar
• CARSON AJ, MACHALE S, ALLEN K et al.: Depression after stroke and lesion location: a systematic review. Lancet (2000) 8(9224):122–126.
   Google Scholar
• CHARATAN FB, FISK A: Mental and emotional results of strokes. NY State J. Med. (1978) 78:1403–1405.
   PubMedGoogle Scholar
• THE SUNNYBROOK STROKE STUDY: Functional and Neuroanatomic Correlations in Poststroke Depression. Stroke (2000) 31:637.
   PubMed Web of Science ®Google Scholar
• GAINOTTI G, AZZONI A, GASPARINI F, MARRA C, RAZZANO C: Relation of lesion location o verbal and non verbal mood measures in stroke patients. Stroke (1997) 28:2145–2149.
   PubMed Web of Science ®Google Scholar
• GAINOTTI G, ANTONUCCI G, MARRA C, PAOLUCCI S: Relation between depression after stroke, antidepressant therapy, and functional recovery. J. Neurol Neurosurg. Psychiatry (2001) 71(2):258–261.
   PubMed Web of Science ®Google Scholar
• KAUHANEN M, KORPELAINEN JT,HILTUNEN P et al.: Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke (1999) 30:1875–1880.
   Google Scholar
• FRUHWALD S, LOEFFLER H, EHER R, SALETU B, BAUMHACKL U: The relationship between depression, anxiety and quality of life - a study of stroke patients compared to chronic low back pain and myocardial ischemia patients. Psychopathology (2001) 34:50–56.
   PubMed Web of Science ®Google Scholar
• KING RB: Quality of life after stroke. Stroke (1996) 27:1467–1472.
   PubMed Web of Science ®Google Scholar
• SUENKELER ICH, NOWAK M, MISSELWITZ B et al: Timecourse of healthrelated quality of life as determined 3, 6 and 12 months after stroke - relationship to neurological deficit, disability and depression. I Neurol. (2002) 249:1160–1167.
   PubMed Web of Science ®Google Scholar
• KOTILA M, NUMMINEN H, WALTIMO O, KASTE M: Depression after stroke: results of the Finnstroke Study. Stroke (1998) 29:368–372.
   PubMed Web of Science ®Google Scholar
• LAURITZEN L, BENDSEN BB,VILMAR T, BENDSEN EB, LUNDE M, BECH P: Post-stroke depression: combined treatment with imipramine or desipramine and mianserin.A controlled clinical study. Psychopharmacology (1994) 114:119–122.
   Google Scholar
• LIPSEY JR, ROBINSON R G, PEARLSON GD, RAO K, PRICE TR: Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet (1984) 11:297–300.
   Google Scholar
• VASWANI M, LINDA FK, RAMESH S: Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Frog. Neuropsychopharmacol Biol. Psychiatry (2003) 27(1):85–102.
   PubMed Web of Science ®Google Scholar
• •A recent and complete review on the neropsychopharmacological features of SSRIs.
   Google Scholar
• SKOP BP, BROWN TM: Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics (1996) 37:12–16.
   PubMed Web of Science ®Google Scholar
• DE ABAJO FJ, GARCIA RODRIGUEZ LA, MONTERO D: Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BM/(1999) 319:1106–1109.
   PubMed Web of Science ®Google Scholar
• VAN WALRAVEN C, MAMDANI MM, WELLS PS, WILLIAMS JI: Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ(2001) 323:1–6.
   PubMedGoogle Scholar
• LAZARUS LW, MOBERG PJ, LANGSLEY PR, LINGAM VR : Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch. Phys. Med. Rehabil (1994) 75(4):403–406.
   PubMed Web of Science ®Google Scholar
• JOHNSON ML, ROBERTS MD, ROSS AR, WITTEN CM: Methylphenidate in stroke patients with depression. Am. I Phys. Med. Rehab:a. (1992) 71(4):239–241.
   PubMed Web of Science ®Google Scholar
• SHIMA S: The efficacy of antidepressants in post-stroke depression. Keio J. Med. (1997) 46 (1):25–26.
   PubMedGoogle Scholar
• GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS,ET AL: Drug interactions with newer antidepressants: role of human cytochromes P450. I Clin. Psychiatry (1998) 59(15):19–?.
   PubMedGoogle Scholar
• KIMURA M, ROBINSON RG, KOSIER JT: Treatment of cognitive impairment after post-stroke depression: a double-blind treatment trial. Stroke (2000) 31(7):1482–1486.
   PubMed Web of Science ®Google Scholar
• ANDERSEN G, VESTERGAARD K, RIIS JO: Citalopram for post-stroke pathological crying. Lancet (1993) 2 342(8875):837–839.
   Google Scholar
• ANDERSEN G: Treatment of uncontrolled crying after stroke. Drugs Aging (1995a) 6(2):105–111.
   PubMed Web of Science ®Google Scholar
• ANDERSEN G, VESTERGAARD K, LAURITZEN LU: Effective treatment of depression following apoplexy with citalopram. Ugeskr. Laeger (19950 3 157(14):2000–2003.
   Google Scholar
• RIGLER SK: Management of poststroke depression in older people. Clin. Ceriatr. Med. (1999) 15(4):765–783.
   PubMed Web of Science ®Google Scholar
• STAMENKOVIC M, SCHINDLER S, KASPER S: Therapy of post-stroke depression with fluoxetine. A pilot project. Nervenarzt. (1996) 67(1):62–67.
   PubMedGoogle Scholar
• DAM M, TONIN P, DE BONI A et al: Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke (1996) 27:1211–1214.
   PubMed Web of Science ®Google Scholar
• PAOLUCCI S, ANTONUCCI G, GRASSO MG et al : Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc. Dis. (2001) 12(3):264–271.
   PubMed Web of Science ®Google Scholar
• CHEER SM, GOA KL: Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs (2001) 61(1):81–110.
   PubMed Web of Science ®Google Scholar
• GOODNICK PJ, HERNANDEZ M: Treatment of depression in comorbid medical illness. Expert. Opin. Pharmacother. (2000) 1(7):1367–1384. An interesting paper about the advisable therapeuthical opportunities for depression after a stroke and in other co-morbid medical illnesses.
   Google Scholar
• SOLAI LK, MULSANT BH, POLLOCK BG: Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging (2001) 18(5)355–368.
   Google Scholar
• ••A very interesting review on this topic withuseful indication about the choice of the SSRI based on the efficacy and safety profile.
   Google Scholar
• BOURIN M: Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review. Hum. PsychopharmacoL (2003) 18(3):185–190.
   PubMed Web of Science ®Google Scholar
• COLE MG, ELIE LM, MCCUSKER J, BELLAVANCE F, MANS OUR A: Feasibility and effectiveness of treatments for post-stroke depression in elderly inpatients: systematic review. J. Ceriatr. Psychiatry Neurol (2001) 14(1):37–41.
   PubMed Web of Science ®Google Scholar
• GUPTA A, PANSARI K, SHETTY H: Post-stroke depression. Int. J. Cliii. Pract. (2002) 56(7):531–537.
   PubMed Web of Science ®Google Scholar
• •An useful review on this topic.
   Google Scholar
• KATAYAMA Y, USUDA K, NISHIYAMA Y, KATSURA K: Post-stroke depression. Nippon Ronen Igakkai Zasshi. (2003) 40(2):127–129.
   PubMedGoogle Scholar
• FRUEHWALD S, GATTERBAUER E, REHAK P, BAUMHACKL U: Early fluoxetine treatment of post-stroke depression. A three-month double-blind placebo-controlled study with an open-label long-term follow up. J. Neurol (2003) 250:347–351.
   Google Scholar
• ••A double-blind, randomised, placebo-controlled study, with a good sample size and a long term, although open-label, follow-up.
   Google Scholar
• SPALLETTA G, CALTAGIRONE C: Sertraline treatment of post-stroke major depression: an open study in patients with moderate to severe symptoms. Funct. Neurol (2003) 18(4):227–232.
   PubMed Web of Science ®Google Scholar
• TURNER-STOKES L, HASSAN N: Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: treatment alternatives. Clin. Rehabil (2002) 16(3):248–260.
   Google Scholar
• ••A review with a very interestingaim(i.e., to establish a more consistent approach to assessment and treatment of PSD) by the development of an evidence-based integrated care pathway.
   Google Scholar
• VAN DE MEENT H, GEURTS AC, VAN LIMBEEK J: Pharmacologic treatment of poststroke depression: a systematic review of the literature. Top. Stroke Rehabil. (2003) 10(1):79–92.
   PubMedGoogle Scholar
• PERETTI S, JUDGE R, HINDMARCH I: Safety and tolerability considerations: tricyclic antidepressants versus selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. (2000) 403:17–25.
   Web of Science ®Google Scholar
• HERRMANN N: Use of SSRIs in the elderly: obvious benefits but unappreciated risks. Can.Pharmacol (2000)7(2):91–95.
   Google Scholar
• BRYMER C, WINOGRAD C: Fluoxetine in elderly patients: is there a cause for concern?' Am. Ceriatr. (1992) 40:902–905.
   Web of Science ®Google Scholar
• ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S: Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am. J. Psychiatry (1994) 151:1735–1739.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, HAMILTON SH, MASICA DN, BEASLEY CM: Fluoxetine in medically stable, depressed geriatric patients: effects on weight. J. Clin. Psychopharmacol (1997) 17:365–369.
   PubMed Web of Science ®Google Scholar
• ROBINSON RG, SCHULTZ SK, CASTILLO C et al.: Nortriptyline Versus Fluoxetine in the Treatment of Depression and in Short-Term Recovery After Stroke: A Placebo-Controlled, Double-Blind Study. Am. J. Psychiatry (2000) 157:351–359.
   PubMed Web of Science ®Google Scholar
• ••The first double-blind, placebo-controlledtrial comparing a TCA with an SSRI antidepressant for PSD.
   Google Scholar
• FRANCO K, MALHOTRA S: Poststroke Depression. Am. J. Psychiatry (2001) 158:658–659.
   PubMed Web of Science ®Google Scholar
• SUSSMAN N, GINSBERG DL: Weight gain associated with SSRIs: a paradox? Primary Psychiatry (1998) 5:28–39.
   Google Scholar
• WILSON K, MOTTRAM P: A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int. J. Ceriatr. Psychiatry (2004) 19(8):754–762.
   PubMed Web of Science ®Google Scholar
• RAMPELLO L, CHIECHIO S, NICOLETTI G et al.: Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Ben.) (2004) 173(1-2):73–78.
   PubMed Web of Science ®Google Scholar
• ••How to classify PSD according to theclinical profile for the selection of SSRIs or as drugs of choice in particular subgroups of patients.
   Google Scholar
• RAMPELLO L, NICOLETTI G, RAFFAELE R, DRAGO F: Comparative effects of Amitriptyline and Amineptine in patients affected by anxious depression. Neuropsycobiology (1995) 31:130–134.
   PubMed Web of Science ®Google Scholar
• RAMPELLO L, NICOLETTI G, RAFFAELE R: Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatr. Scand. (1991) 84:552–554.
   PubMed Web of Science ®Google Scholar
• RAMPELLO L, NICOLETTI F, NICOLETTI F: Dopamine and depression. Therapeutic implications. CNS Drugs (2000) 13(1):35–45.
   Web of Science ®Google Scholar
• RAMPELLO L, ALVANO A, CHIECHIO S, RAFFAELE R, VECCHIO I, MALAGUARNERA M: An evaluation of efficacy and safety of reboxetine in elderly patients affected by 'retarded' post-stroke depression A random, placebo-controlled study. Arch. Cerontol Ceriatr. (2005) 40(3):275–285.
   Google Scholar
• DAHMEN N, MARX J, HOPE HC, TETTENBORN B, RODER R: Therapy of early poststroke depression with venlafaxine: safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial. Stroke (1999) 30:691–692.
   PubMed Web of Science ®Google Scholar
• THASE ME: Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. Clin. Psychiatry (1998) 59:502–508.
   PubMed Web of Science ®Google Scholar
• KIMURA M, KANETANI K, IMAI R, SUZUKI H, ISAYAMA K, ENDO S: Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int. Clin. Psychopharmacol (2002) 17(3):121–125.
   PubMed Web of Science ®Google Scholar
• GEKHT AB, SOROKINA IB, BOGOLEPOVA AN, GUDKOVA AA: Experience with ixel (milnacipran hydrochloride) use in the treatment of patients with post-stroke depression. Ter. Arkh. (2003) 75(10):34–38.
   PubMed Web of Science ®Google Scholar
• REDING MJ, ORTO LA, WINTER SW, FORTUNA IM, DI PONTE P, MCDOWELL FH: Antidepressant therapy after stroke: a double-blind trial. Arch. Neurol (1986) 43:763–765.
   PubMed Web of Science ®Google Scholar
• DARKO W, GUHAROY R, ROSE F, LEHMAN D, PAPPAS V: Myoclonus secondary to the concurrent use of trazodone and fluoxetine. Vet. Hum. Toxicol (2001) 43(4):214–215.
   PubMedGoogle Scholar
• McCUE Rand JOSEPH M: Venlafaxine- and trazodone-induced serotonin syndrome. Am. J. Psychiatry (2001) 158.2088–2089.
   PubMed Web of Science ®Google Scholar
• PRAPOTNIK M, WASCHGLER R, KONIG P, MOLL W, CON CA A: Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int.). Clin. Pharmacol Ther. (2004) 42(2):120–124.
   Google Scholar
• SMALL NL and GIAMONNA KA: Interaction between warfarin and trazodone. Ann. Pharmacother. (2000) 34(6):734–736.
   PubMed Web of Science ®Google Scholar
• HOUGAKU H, MATSUMOTO M, HATA R et al: Therapeutic effect of lisuride maleate on post-stroke depression. Nippon Ronen Igakkai Zasshi (1994) 31(1):52–59.
   PubMedGoogle Scholar
• GEORGOTAS A, MCCUE RE, HAPWORTH W, FRIEDMAN E, KIM OM, WELKOWITZ J et al: Comparative efficacy and safety of MAOI versus TCA's in treating depression in the elderly. Biol. Psychiatry (1986) 21:1155–66.
   PubMed Web of Science ®Google Scholar
• GEORGOTAS A, MCCUE RE, FRIEDMAN E et al.: A placebo-controlled comparison of nortriptyline and phenelzine on orthostatic hypotension in elderly depressed patients. I Clin. Psychopharmacol (1987) 7:413–416.
   Google Scholar
• LAZARUS LW, GROVES L, GIERL B, PANDEY G, JAVAID I, LESSER J et al: Efficacy of phenelzine in geriatric depression. Biol. Psychiatry (1986) 21:699–701.
   PubMed Web of Science ®Google Scholar
• TOURIGNY-RIVARD ME Pharmacotherapy of affective disorders in old age. Can. J. Psychiatry (1997) 42(1):10S-185.
   Google Scholar
• KATO M, IWATA H, KATAYAMA T, ASAI H, NARITA H, ENDO T: Possible therapeutic effect of T-794, a novel reversible inhibitor of monoamine oxidase-A, on post-stroke emotional disturbances, assessed in animal models of depression. Biol. Pharm. Bull. (1997) 20(4):349–353.
   PubMed Web of Science ®Google Scholar
• KUBIN A, WIERRANI F, BURNER U, ALTH G, GRUNBERGER W: Hypericin-the facts about a controversial agent. Curr. Pharm. Des. (2005) 11(2):233–253.
   PubMed Web of Science ®Google Scholar
• BRENNER R, AZBEL V, MADHUSOODANAN S, PAWLOWSKA M: Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Ther. (2000) 22(4):411–419.
   Google Scholar
• FRIEDE M, HENNEICKE VON ZEPELIN HH, FREUDENSTEIN J: Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. Pharmacopsychiatry (2001) 34(S1):538–541.
   Google Scholar
• PACHER P, KECSKEMETI V: Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr. Pharm. Des. (2004) 10(20):2463–2475.
   Google Scholar
• •A light on the recently observed clinically important cardiovascular effects of SSRIs.
   Google Scholar
• RAMASUBBU R: Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. ./. Clin. Psychiatry (2004a) 65(12):1642–1653.
   PubMed Web of Science ®Google Scholar
• ••Available evidence on the cerebrovascularside effects of SSRIs.
   Google Scholar
• RAMASUBBU R: SSRI treatment-associated stroke: causality assessment in two cases. Ann. Pharmacother. (2004b) 38(7-8):1197–1201.
   PubMed Web of Science ®Google Scholar
• DE ABAJO FJ, JICK H, DERBY L, JICK S, SCHMITZ S: Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. BE J. Clin. Pharmacol (2000) 50:43–47.
   PubMed Web of Science ®Google Scholar
• HERGOVICH N, AIGNER M, EICHLER HG, ENTLICHER J, DRUCKER C, JILMA B: Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin. Pharmacol Ther. (2000) 68(4):435–442.
   PubMed Web of Science ®Google Scholar
• SEREBRUANY VL, GURBEL PA, O'CONNOR CM: Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between Depression, coronary events, and mortality benefits of Selective serotonin reuptake inhibitors. Pharmacological. Research. (2001) 43:5.
   Google Scholar
• BAK S, TSIROPOULOS I, KLERSGAARD JO et al: Selective serotonin reuptake inhibitors and the risk of stroke. A population-based case-control study. Stroke (2002) 33:1465.
   Google Scholar
• •A nested control study n the association between SSRIs use and the risk of stroke.
   Google Scholar
• MEIER CR, SCHLIENGER RG, JICK H:Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br. J. Clin. Pharmacol( 2001) 52:179–184.
   PubMed Web of Science ®Google Scholar
• SAUER WH, BERLIN JA, KIMMEL SE: Selective serotonin reuptake inhibitors and myocardial infarction. Circulation (2001) 104:1894–1898.
   PubMed Web of Science ®Google Scholar
• EVERSON SA, ROBERTS RE, GOLDBERG DE, KAPLAN GA: Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch. Intern. Med. (1998) 158:1133–1138.
   PubMed Web of Science ®Google Scholar
• LARSON SL, OWENS PL, FORD D, EATON W: Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore Epidemiologic Catchment Area Study. Stroke (2001) 32:1979–1983.
   PubMed Web of Science ®Google Scholar
• KRISHNAN KR: Depression as a contributing factor in cerebrovascular disease. Am. Heart. J. (2000) 140:S70–S76.
   Google Scholar
• LAYTON D, CLARK DW, PEARCE GL, SHAKIR SA: Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur. Clin. Pharmacol (2001) 57:167–176.
   Web of Science ®Google Scholar
• KURNE A, ERTUGRUL A, ANIL YAGCIOGLU AE, YAZICI KM: Venous thromboembolism and escitalopram. Gen. Hosp. Psychiatry (2004) 26(6):481–483.
   PubMed Web of Science ®Google Scholar
• GLASSMAN AH, SHAPIRO PA: Depression and the course of coronary artery disease. Am. J. Psychiatry (1998) 155:4–11.
   PubMed Web of Science ®Google Scholar
• MUSSELMAN DL, EVANS DL, NEMEROFF CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry (1998) 55:580–592.
   PubMed Web of Science ®Google Scholar
• LESPERANCE F, JUNEAU M, THEROUX P: Depression and 1-year prognosis in unstable angina. Arch. Intern. Med. (2000) 160:1354–1360.
   PubMed Web of Science ®Google Scholar
• LESPERANCE F, FRASURE-SMITH N, TALAJIC M et al: Five-year risk of cardiac mortality in relation to initial severity and 1-year changes in depression symptoms after myocardial infarction. Circulation (2002) 105:1049–1053.
   PubMed Web of Science ®Google Scholar
• MUSSELMAN DL, TOMER A, MANATUNGA AK et al: Exaggerated platelet reactivity in major depression. Am. J. Psychiatry (1996) 153:1313–1317.
   PubMed Web of Science ®Google Scholar
• COHEN HW, GIBSON G, ALDERMAN MH: Excess risk of myocardial infarction in patients treated with antidepressant medication: association with use of tricyclic agents. Am. J. Med. (2000) 108(1):2–8.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN A, LUNDE M, POULSEN DL, SORENSEN K, QVITZAU S, BECH P: A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics (2003) 44:216–221.
   PubMed Web of Science ®Google Scholar
• SEREBRUANY VL, GLASSMAN AH, MALININ Al et al. FOR THE SADHART STUDY GROUP: Platelet/ biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after endothelial acute coronary events. The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation (2003) 108:939.
   Google Scholar
• GLASSMAN AH, PREUD'HOMME XA: Review of the cardiovascular effects of heterocyclic antidepressants. ./. Psychiatry (1993) 54\(Suppl. 2):16–22.
   Google Scholar
• ROOSE SP, GLASSMAN AH, GIARDINA EG, JOHNSON LL, WALSH BT, WOODRING S, BIGGER JT: Nortriptyline in depressed patients with left ventricular impairment. JAMA (1986) 256:3253–3257.
   PubMed Web of Science ®Google Scholar
• DAVIES SJ, JACKSON PR, POTOKAR J, NUTT DJ: Treatment of anxiety and depressive disorders in patients with cardiovascular disease. BM/(2004) 328(7445)939–943.
   Google Scholar
• ROOSE SP, LAGHRISSI-THODE F, KENNEDY JS et al.: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA (1998) 279:287–291.
   PubMed Web of Science ®Google Scholar
• FAVA M, ROSENBAUM JF, PAVA JA, MCCARTHY MK, STEINGARD RJ, BOUFFIDES E: Anger attacks in unipolar depression, Part 1: Clinical correlates and response to fluoxetine treatment. Am. J. Psychiatry (1993) 150(8):1158–1163.
   PubMed Web of Science ®Google Scholar
• BERTHIER ML, KULISEVSKY J: Fluoxetine-induced mania in a patient with post-stroke depression. BE J. Psychiatry (1993) 163:698–699.
   PubMed Web of Science ®Google Scholar
• KULISEVSKY J, BERTHIER ML: A new case of fluoxetine-induced mania in poststroke depression. Clin. Neuropharmacol (1997) 20(2):180–181.
   PubMed Web of Science ®Google Scholar
• DE LEON OA, FURMAGA KM, KALTSOUNIS J: Mirtazapine-Induced Mania in a Case of Poststroke Depression. Neuropsychiatry Clin. Neurosci. (1999) 11:115–116.
   Web of Science ®Google Scholar
• KIMURA M, TATENO A, ROBINSON RG: Treatment of poststroke generalized anxiety disorder comorbid with poststroke depression merged analysis of nortriptyline trials. Am. J. Geriatr. Psychiatry (2003) 11:320–327.
   PubMed Web of Science ®Google Scholar
• PRESKORN SH: Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes./. Psychopharmacol. (1998) 12(3 Suppl. B):S89–S97.
   Google Scholar
• ROGER J, CADIEUX MD: Antidepressant drug interactions in the elderly. Understanding the P450 system is half the battle in reducing risks. Postgraduate medicine online (1999) 106:(6).
   Google Scholar
• MICHALETS EL: Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy (1998) 18(1):84–112.
   PubMed Web of Science ®Google Scholar
• PALOMAKI H, KASTE M, BERG A et al: Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy. J. Neurol. Neurosurg. Psychiatry (1999) 66:490–494.
   PubMed Web of Science ®Google Scholar
• NARUSHIMA K, KOSIER JT, ROBINSON RG: Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up./. Nerv. Ment. Dis. (2002) 190(5)296–303.
   Google Scholar
• JORGE RE, ROBINSON RG, ARNDT S, STARKSTEIN S: Mortality and Poststroke Depression: A Placebo-Controlled Trial of Antidepressants. Am. J. Psychiatry (2003) 160:1823–1829.
   PubMed Web of Science ®Google Scholar
• HEGERL U, MOLLER HJ: Pharmacotherapy of depression in the elderly. Nervenarzt. (2000) 71(1):1–8.
   PubMed Web of Science ®Google Scholar
• JAKOVLJEVIC D, TUOMILEHTO: Use of selective serotonin reuptake inhibitors and the risk of stroke: is there reason for concern? Stroke (2002) 33:1448.
   PubMed Web of Science ®Google Scholar
• MACKAY FJ, DUNN NR, WILTON LV, PEARCE GL, FREEMANTLE SN, MANN RD: A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol. Drug Sal: (1997) 6(4):235–246.
   PubMed Web of Science ®Google Scholar
• SPALLETTA G, GUIDA G, CALTAGIRONE C: Is left stroke a risk-factor for selective serotonin reuptake inhibitor antidepressant treatment resistance?' Neurol. (2003) 250(4):449–455.
   Google Scholar
• GHOGE H, SHARMA S, SONAWALLA S, PARIKH R: Cerebrovascular diseases and depression. Curr. Psychiatry Rep. (2003) 5 (3) : 231–238.
   PubMedGoogle Scholar
• SCHUBERT D, BURNS R, PARAS W et al.: Decrease of depression during stroke and amputation rehabilitation. Gen. Hosp. Psychiatry (1992) 14:135–141.
   PubMed Web of Science ®Google Scholar
• COSTA E SILVA JA: From restoration of neuroplasticity to the treatment of depression: clinical experience. Eur. Neuropsychopharmacol. (2004) 14\(Suppl. 5):5511–5521.
   Google Scholar
• MALBERG JE: Implications of adult hippocampal neurogenesis in antidepressant action. J. Psychiatry Neurosi. (2004) 29(3):196–205.
   PubMed Web of Science ®Google Scholar
• MALBERG JE, SCHECHTER LE: Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr. Pharm. Des. (2005) 11(2):145–155.
   PubMed Web of Science ®Google Scholar
• SAIRANEN M, LUCAS M, ERNFORS P, CASTREN M, CASTREN E: Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus./. Neurosci. (2005) 25(5):1089–1094.
   Google Scholar
• KODAMA M, FUJIOKA T, DUMAN RS: Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry (2004) 56(8):570–580.
   PubMed Web of Science ®Google Scholar
• AICHNER F, ADELWOHRER C, HARING HP: Rehabilitation approaches to stroke. J. Neural. Transm. Suppl. (2002) 63:59–73.
   PubMedGoogle Scholar